Related Experiment Video

Updated: May 26, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy

Adel Almogren1, Julia Abdullah, Kshipra Ghapure

  • 1Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Frontiers in Bioscience (Scholar Edition)
|December 29, 2011
PubMed

Insights

Thomsen-Friedenreich antigen (TF-Ag) is found on most carcinomas and promotes cancer spread. Targeting TF-Ag with antibodies may inhibit metastasis and improve patient outcomes, making it a promising vaccine target.

Area of Science:

  • Oncology
  • Glycobiology
  • Immunology

Background:

  • Thomsen-Friedenreich antigen (TF-Ag), a core 1 structure disaccharide, is aberrantly expressed on ~90% of carcinomas.
  • TF-Ag contributes to tumor cell adhesion and metastasis.
  • Naturally occurring antibodies to TF-Ag correlate with improved patient prognosis.

Purpose of the Study:

  • To evaluate TF-Ag as a potential therapeutic target for cancer treatment.
  • To investigate the role of TF-Ag in cancer metastasis and prognosis.
  • To assess the feasibility of targeting TF-Ag for vaccine development.

Main Methods:

  • Treatment of a mouse breast cancer model with JAA-F11 monoclonal antibody against TF-Ag.
  • Analysis of TF-Ag expression in various carcinomas.
  • Correlation of naturally occurring anti-TF-Ag antibodies with clinical outcomes.

Main Results:

  • Antibody treatment targeting TF-Ag inhibited lung metastasis and improved prognosis in a mouse model.
  • Pancarcinoma expression of TF-Ag was confirmed.
  • The presence of natural antibodies suggests safety and feasibility for immune-based therapies.

Conclusions:

  • TF-Ag is a clinically relevant target due to its widespread expression and role in metastasis.
  • Enhancing anti-TF-Ag antibody responses is a safe and potentially effective strategy.
  • TF-Ag represents a significant target for cancer vaccine development.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...